Genentech to Present New OCREVUS (Ocrelizumab) Data on MS

• New analyses show the effect of OCREVUS on reducing the risk of disability progression is associated with exposure and lower B-cell levels
• Long-term data in RMS and PPMS show that earlier treatment with OCREVUS significantly reduced the risk of permanent disability progression
• Over 100,000 people have been treated with OCREVUS globally, in clinical trial and real-world settings; data presented at the AAN Annual Meeting highlights a consistent and favorable benefit-risk profile

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new OCREVUS^® (ocrelizumab) data in relapsing and primary progressive multiple sclerosis (MS) were presented at the 71st American Academy of Neurology (AAN) Annual Meeting from May 4-10 in Philadelphia, Pennsylvania. New analyses on OCREVUS show its effect on reducing the risk of disability progression is associated with higher exposure to the medicine and lower B-cell levels, and show the positive impact of OCREVUS in significantly reducing disability progression.

https://www.businesswire.com/news/home/20190507006191/en/Genentech-Present-New-OCREVUS-Ocrelizumab-Data-Analyses